<DOC>
	<DOCNO>NCT00310791</DOCNO>
	<brief_summary>This study seek gain new information young woman anorexia nervosa predispose early bone loss osteoporosis . Through randomize treatment trial participant receive either combined therapy adrenal hormone , dehydroepiandrosterone ( DHEA ) estrogen replacement therapy placebo , determine effect 18-month treatment course bone mass , circulate marker bone turnover , serum level factor , insulin-like growth factor I ( IGF-I ) . We also study therapy change bone structure increase skeletal strength compare placebo , assess cross-sectional geometric analysis bone density data dual-energy x-ray absorptiometry ( DXA ) .</brief_summary>
	<brief_title>Adrenal Gonadal Hormone Replacement Anorexia Nervosa</brief_title>
	<detailed_description>Profound osteopenia frequent often irreversible complication anorexia nervosa ( AN ) . Adolescents AN often reduce peak bone mass increase risk early osteoporosis fracture . These young woman subnormal serum level gonadal steroid adrenal androgen dehydroepiandrosterone ( DHEA ) may associate low bone mineral density ( BMD ) . Low DHEA level accompany decreased level insulin-like growth factor I ( IGF-I ) , estrogen , testosterone . Previous data group indicate oral DHEA therapy young woman AN : increase lean body mass , serum level bone formation marker insulin-like growth factor I ( IGF-I ) , decrease urinary marker bone resorption . We also find standard hormonal replacement therapy ( HRT ) significantly decrease bone resorption marker . Information effect therapies bone strength ultimate fracture risk lack . In project , test hypothesis combine therapy DHEA estrogen/progestin enhance bone mass patient AN anabolic antiosteolytic mechanism . We test hypothesis 18 month DHEA + HRT increase bone mineral density ( BMD ) markers bone formation , decrease bone resorption marker patient . The propose study examine whether restore normal level DHEA estrogen young woman increase bone mass critical period bone accretion . The study also examine whether DHEA 's anabolic effect bone mediate skeletal IGF-I regulatory system . Using cross-sectional analysis dual energy x-ray absorptiometry ( DXA ) data , also measure indices bone structural geometry determine mechanical strength compromise young woman , strength restore response combine anabolic/antiresorptive therapy . To gain new information mechanism underlie bone loss fracture risk young woman AN , research goal : Specific Aim I : Through randomize control trial , measure effect 18-month course DHEA + HRT bone mass , marker bone turnover , serum level IGF-I compare placebo . Specific Aim II : To determine whether combined therapy adrenal gonadal steroid replacement change bone structure increase strength compare placebo , assess cross-sectional geometric analysis DXA data .</detailed_description>
	<mesh_term>Anorexia Nervosa</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>Age 15 30 year Anorexia nervosa psychiatric criterion Amenorrhea least 3 month Receiving medication know affect bone metabolism No chronic medical condition</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>anorexia nervosa</keyword>
	<keyword>adolescent</keyword>
	<keyword>dual-energy x-ray absorptiometry</keyword>
	<keyword>dehydroepiandrosterone ( DHEA )</keyword>
	<keyword>osteoporosis</keyword>
</DOC>